Status:
TERMINATED
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2 Diabetes Mellitus.
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus
- Female subjects must be non-pregnant and non-lactating
Exclusion
- Recurrent severe hypoglycemia or hypoglycemic unawareness or recent severe ketoacidosis, as judged by the Investigator
- Pregnant or lactating women
- Participation in an investigational study within 30 days prior to dosing
Key Trial Info
Start Date :
October 25 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT03332836
Start Date
October 25 2017
End Date
September 30 2020
Last Update
April 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanmi Investigative Site
Chula Vista, California, United States, 91911